Trial Profile
A longitudinal safety and efficacy study of abatacept evaluating the effect of age on risk-benefit ratio in patients with rheumatoid arthritis enrolled in the French Society of Rheumatology's ORA registry
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 13 Jan 2021
Price :
$35
*
At a glance
- Drugs Abatacept (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms ORA registry
- 11 Feb 2016 New trial record
- 27 Jan 2016 Results published in the Rheumatology